Both lesions may share the same immuno-morphological features, such as a clear cell morphology and positivity for CD30; however, strong CD30, CD23 and MAL expression favors PM-LBCL over PP-DLBCL [4]. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.